Fondaparinux

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Fondaparinux and local guidelines before prescribing.

Factor Xa inhibitor

Mechanism

Synthetic pentasaccharide factor Xa inhibitor.

Uses

VTE prophylaxis and treatment, ACS, heparin-induced thrombocytopenia (alternative).

Dosing

6 more dose entries from the chapters
  • VTE prophylaxis in hospital (NICE NG89) - assess every adult on admission for VTE and bleeding risk; LMWH (e.g. enoxaparin 40 mg daily, adjusted for weight and kidney function) or fondaparinux; mechanical options (intermittent pneumatic compression - not anti-embolism stockings in acute stroke ); reassess regularly.
    Haematology: Anatomy Physiology and Pharmacology
  • Superficial vein thrombosis - NSAIDs and compression. Fondaparinux 2.5 mg daily for 45 days if 5 cm or longer, or near the saphenofemoral junction (within 3 cm - then scan, as it may need full treatment).
    Haematology: Haemostasis and Thrombosis
  • LMWH (e.g. enoxaparin 40 mg once daily ; 20 mg if creatinine clearance is under 30), or fondaparinux, for at least 7 days if risk outweighs bleeding risk.
    Haematology: Haemostasis and Thrombosis
  • Fondaparinux 2.5 mg daily | Superficial vein thrombosis (45 days); HIT alternative.
    Haematology: Haemostasis and Thrombosis
  • Treatment - aspirin 300 mg, fondaparinux (unless angiography soon), second antiplatelet per protocol, beta-blocker, GTN; risk-stratify with GRACE - angiography within 72 hours for intermediate or higher risk (see the Cardiology chapters).
    Acute Medicine: Acute chest pain, breathlessness, collapse and blood gases
  • Pharmacological prophylaxis - LMWH (e.g. enoxaparin 40 mg daily - adjust for weight and kidney function) or fondaparinux, for at least 7 days if VTE risk outweighs bleeding risk; unfractionated heparin in severe kidney impairment (eGFR under 15–30).
    Acute Medicine: The acute medical take

Side effects

Bleeding, anaemia, injection-site reactions.

Interactions

Anticoagulants and antiplatelets.

Contraindications and cautions

Active bleeding, CrCl below 20, endocarditis

Monitoring

Renal function, Hb

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Avoid if CrCl below 20

Overdose and reversal

Andexanet or prothrombin complex concentrate

Special advice

Contraindicated if CrCl below 20; no HIT risk.

More from the textbook: uses, cautions and other points
Where it is discussed in the book